Contents

Contributors xvii
Series Foreword xx
Preface xxiii
Abbreviations xxvii

Ethnopharmacology: The Fundamental Challenges

1 Ethnopharmacology: A Short History of a Multidisciplinary Field of Research 3
   Michael Heinrich
   1.1 Introduction 3
   Acknowledgements 8
   References 8

2 Medicinal Plant Research: A Reflection on Translational Tasks 11
   Anna K Jäger
   2.1 Introduction 11
   2.2 Translational research: preclinical research 12
   2.3 Translational research: clinical research 13
   2.4 Reaching the patient 14
   2.5 A ‘developed’ traditional medicine system 14
   References 16

3 The Anthropology of Ethnopharmacology 17
   Ina Vandebroek and Daniel E. Moerman
   3.1 Introduction 17
   3.2 Primary example: Traditional medicine in New York City 18
   3.2.1 Missing out on cultural context 19
   3.2.2 People change plants due to availability 20
   3.2.3 The spiritual component 21
   3.3 An example from ancient Roman architecture 22
   3.4 An example from native North America 23
3.5 Comparative ethnobotany 24
3.6 Conclusions 26
References 27

4 Quantitative and Comparative Methods in Ethnopharmacology 29
Marco Leonti and Caroline S. Weckerle

4.1 Introduction 29
4.1.1 Materia medica and cultural consensus 29
4.1.2 The intent of ethnopharmacological projects: Basic and applied research 30
4.1.3 Ethnopharmacology as cross-cultural endeavour and the concept of emic and etic 30
4.2 Research questions 31
4.2.1 Descriptive questions 32
4.2.2 Relational questions 32
4.3 Field research 33
4.3.1 Data sampling 33
4.4 Analyzing the data 34
4.4.1 Use-reports for quantification 34
4.5 Pharmacological research 35
4.6 Contextualization 36
4.7 Conclusion 37
References 37

5 Biodiversity, Conservation and Ethnopharmacology 41
Vernon H. Heywood

5.1 Introduction 41
5.2 Changing attitudes to the ownership of biodiversity 42
5.3 Medicinal and aromatic plants as resources 43
5.4 How many species? 44
5.5 Chemical diversity 45
5.6 Wild harvesting and over-collection 45
5.7 Medicinal plant conservation 46
5.8 Conservation approaches 46
5.9 Protected areas 47
5.10 Community conservation 47
5.11 Genetic conservation 47
5.12 Cultivation 48
5.13 Conclusions 48
References 49

6 Ecopharmacognosy 53
Geoffrey A. Cordell

6.1 Introduction 53
6.2 Sustainable medicines and pharmacognosy 54
6.3 Ecopharmacognosy: background 55
6.4 Ecopharmacognosy practices 55
6.4.1 Replacement plant parts 56
6.4.2 Vegetables as chemical reagents 56
6.4.3 The ‘Medicine Man’ approach and remote sensing 56
6.4.4 Dereplication 57
6.4.5 In silico evaluation of natural products 57
6.4.6 Biosynthesis of secondary metabolites 58
6.4.7 Complex traditional medicines 58
<table>
<thead>
<tr>
<th>CONTENTS</th>
<th>vii</th>
</tr>
</thead>
<tbody>
<tr>
<td>6.4.8</td>
<td>Network pharmacology 59</td>
</tr>
<tr>
<td>6.4.9</td>
<td>Can ecopharmacognosy change the dark side of traditional medicine? 59</td>
</tr>
<tr>
<td>6.5</td>
<td>Conclusions 60</td>
</tr>
<tr>
<td></td>
<td>Acknowledgements 60</td>
</tr>
<tr>
<td></td>
<td>References 60</td>
</tr>
</tbody>
</table>

7  NMR-based Metabolomics and Hyphenated NMR Techniques: A Perfect Match in Natural Products Research 63

Joachim Møllesøe Vinther, Sileshi Gizachew Wubshet and Dan Staerk

| 7.1      | Introduction 63 |
|          | Metabolomics 64 |
| 7.3      | Principles of NMR-based metabolomics 65 |
| 7.4      | NMR-based metabolomics in natural products research 66 |
| 7.5      | Hyphenated NMR techniques 68 |
| 7.6      | Principle of HPLC-SPE-NMR 69 |
| 7.7      | High-resolution bioassay-coupled HPLC-SPE-NMR 70 |
| 7.8      | Combining metabolomics and hyphenated NMR techniques 71 |
| 7.9      | Perspectives in ethnopharmacology 72 |
| 7.10     | Conclusions 72 |
|          | References 72 |

8  New Medicines Based On Traditional Knowledge: Indigenous and Intellectual Property Rights from an Ethnopharmacological Perspective 75

Michael Heinrich

| 8.1      | Introduction 75 |
| 8.2      | The legal framework 76 |
| 8.3      | Industrial research in an ethnopharmacological context 77 |
| 8.4      | Some case studies 79 |
| 8.4.1    | Pure natural products as drug leads 79 |
| 8.4.2    | Extracts and partially purified preparations as drug leads 81 |
| 8.5      | Conclusions 83 |
|          | Note 84 |
|          | References 84 |

9  Ethnopharmacology and Intellectual Property Rights 87

Alan Hesketh

| 9.1      | Introduction 87 |
| 9.2      | Indigenous community rights and traditional knowledge 88 |
| 9.3      | Identifying a partner 89 |
| 9.3.1    | The foreign partner’s attitude 90 |
| 9.3.2    | The advantages of IP 90 |
| 9.4      | Hurdles in considering IP 91 |
| 9.5      | Building an effective IP portfolio 91 |
| 9.5.1    | Requirements for patentability 92 |
| 9.5.2    | The value of different types of patent protection 92 |
| 9.6      | The patentability of products of nature 93 |
| 9.6.1    | Novelty 94 |
| 9.6.2    | Novelty and traditional knowledge 94 |
| 9.6.3    | Obviousness 94 |
| 9.7      | Conclusion 95 |
|          | References 95 |
## 10 Ethnopharmacology in Elementary, Primary and Secondary Education: Current Perspectives and Future Prospects

_Alonso Verde, Diego Rivera, José Ramón Vallejo, José Fajardo, Concepción Obón and Arturo Valdés_

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>10.1 Introduction</td>
<td>97</td>
</tr>
<tr>
<td>10.2 Ethnopharmacology: a multidisciplinary subject for education</td>
<td>99</td>
</tr>
<tr>
<td>10.3 Developing an ethnopharmacological curriculum: some strategies</td>
<td>101</td>
</tr>
<tr>
<td>10.4 Conclusions</td>
<td>104</td>
</tr>
<tr>
<td>References</td>
<td>105</td>
</tr>
</tbody>
</table>

### The Pharmacological Angle

## 11 Anti-infective Agents: The Example of Antibacterial Drug Leads

_Maira Bidart de Macedo, Sofie Clais, Ellen Lanckacker, Louis Maes, Emerson Silva Lima and Paul Cos_

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>11.1 Introduction</td>
<td>111</td>
</tr>
<tr>
<td>11.2 Bacterial resistance</td>
<td>112</td>
</tr>
<tr>
<td>11.3 Plant-derived antibacterial agents</td>
<td>112</td>
</tr>
<tr>
<td>11.3.1 Direct antibacterial agents</td>
<td>112</td>
</tr>
<tr>
<td>11.3.2 Antivirulence agents</td>
<td>113</td>
</tr>
<tr>
<td>11.3.3 Resistance-modifying agents</td>
<td>117</td>
</tr>
<tr>
<td>11.4 Basic requirements for successful antimicrobial drug discovery (Cos et al., 2006)</td>
<td>118</td>
</tr>
<tr>
<td>11.5 Conclusion</td>
<td>119</td>
</tr>
<tr>
<td>References</td>
<td>120</td>
</tr>
</tbody>
</table>

## 12 Searching for New Treatments of Malaria

_Colin W. Wright_

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>12.1 Introduction</td>
<td>123</td>
</tr>
<tr>
<td>12.2 Traditional herbal remedies as a source of antimalarial lead compounds</td>
<td>123</td>
</tr>
<tr>
<td>12.3 Developments from established antimalarials</td>
<td>126</td>
</tr>
<tr>
<td>12.4 Non-traditional medicine sources of potential antimalarials</td>
<td>127</td>
</tr>
<tr>
<td>12.5 Alternative strategies in the search for natural antimalarial compounds</td>
<td>129</td>
</tr>
<tr>
<td>12.6 Herbal preparations for the treatment of malaria</td>
<td>130</td>
</tr>
<tr>
<td>12.7 Conclusion and future prospects</td>
<td>132</td>
</tr>
<tr>
<td>References</td>
<td>132</td>
</tr>
</tbody>
</table>

## 13 CNS Disorders

_Anna K Jäger_

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>13.1 Introduction</td>
<td>135</td>
</tr>
<tr>
<td>13.2 Epilepsy</td>
<td>135</td>
</tr>
<tr>
<td>13.3 Depression and anxiety</td>
<td>137</td>
</tr>
<tr>
<td>13.3.1 Selective serotonin reuptake inhibitors</td>
<td>137</td>
</tr>
<tr>
<td>13.3.2 MAO-A inhibitors</td>
<td>138</td>
</tr>
<tr>
<td>13.3.3 Clinical evidence</td>
<td>138</td>
</tr>
<tr>
<td>13.4 Insomnia</td>
<td>139</td>
</tr>
<tr>
<td>13.5 Sedatives</td>
<td>139</td>
</tr>
<tr>
<td>13.6 Dementia</td>
<td>139</td>
</tr>
<tr>
<td>13.6.1 Countering neurotransmitter abnormalities: acetylcholinesterase inhibitors</td>
<td>140</td>
</tr>
<tr>
<td>13.6.2 Countering neurotransmitter abnormalities: MAO-B inhibitors</td>
<td>140</td>
</tr>
</tbody>
</table>
13.6.3 Reducing the formation and fibrillation of amyloid β peptides 141
13.6.4 Anti-inflammatory and antioxidant activity 141
13.7 Conclusion 142
References 142

14 Respiratory Conditions 147
Adolfo Andrade-Cetto and Jorge García-Alvarez

14.1 Introduction 147
14.1.1 The respiratory system 147
14.1.2 Respiratory diseases 147
14.1.3 Common cold 148
14.1.4 Influenza 149
14.1.5 Acute lower respiratory tract infections: acute bronchitis 149
14.1.6 Other diseases of the upper respiratory tract: allergic rhinitis and rhinitis 149
14.1.7 Chronic lower respiratory tract diseases: COPD 149
14.1.8 Lung diseases caused by external agents: hypersensitivity pneumonitis 150
14.1.9 Other respiratory diseases principally affecting the interstitium: idiopathic pulmonary fibrosis 150
14.1.10 Suppurative and necrotic lower respiratory tract conditions: pneumonia with necrosis 150
14.1.11 Other pleural diseases: pleural plaque 151
14.1.12 Other diseases of the respiratory system: acute respiratory failure 151

14.2 Case studies 151
14.2.1 Althaea officinalis L. Malvaceae 152
14.2.2 Codeine and noscapine 153
14.2.3 Echinacea purpurea (L.) Moench and Echinacea angustifolia DC. 153
14.2.4 Ephedra sinica Stapf. (Ephedraceae) 154
14.2.5 Thymus vulgaris L. (Lamiaceae) 155

14.3 Conclusions 155
Acknowledgments 156
References 156

15 Can there be an Ethnopharmacology of Inflammation? 159
Michael Heinrich and Anthony Booker

15.1 Introduction 159
15.2 Ethnopharmacology of inflammation: some examples 161
15.2.1 The arnica complex 162
15.2.2 Harpagophytum procumbens (Burch.) DC. ex Meisn. (Pedaliaceae) 163
15.2.3 Scutellaria baicalensis Georgi (Huang Qin, Baical skullcap; Lamiaceae) 164
15.2.4 Curcuma longa L. (Zingiberaceae) 164
15.2.5 Capsicum frutescens L. 165

15.3 Conclusions 166
References 166

16 Epidermal Growth Factor Receptors and Downstream Signalling Pathways as Cancer Treatment Targets for Medicinal Plants 169
Ean-Jeong Seo, Ching-Fen Wu, Henny J. Greten and Thomas Efferth

16.1 Role of epidermal growth factor receptors for cancer biology 169
16.2 Inhibition of epidermal growth factor signalling by phytochemicals and medicinal plants 171
16.2.1 Natural products as a resource for cancer treatment 171
16.2.2 Inhibitors of EGFR signalling 171
16.2.3 Inhibitors of HER2/HER3 signalling 172
16.3 Conclusions and perspectives 173
References 174

17 From Ethnopharmacological Field Study to Phytochemistry and Preclinical Research: The Example of Ghanaian Medicinal Plants for Improved Wound Healing
Andreas Hensel, Emelia Kisseih, Matthias Lechtenberg, Frank Petereit, Christian Agyare and Alex Asase

17.1 Introduction 179

17.2 Results 180
17.2.1 The start of a research project: validated field study on wound-healing plants 180
17.2.2 Before starting laboratory work: who the healers are and some socioeconomic aspects 180
17.2.3 Evaluation of the data collection and cross-referencing to published literature 181
17.2.4 The next step: selection of plants for in vitro investigations 181
17.2.5 Screening of selected plant extracts: influence on skin cells under in vitro conditions 181
17.2.6 Phytochemical aspects of P. muellerianus and the ICH-validated HPLC method for quality control (ICH, 2014) 190
17.2.7 Influence of P. muellerianus on the cell physiology of human skin cells 192
17.2.8 Phytochemistry of C. mucronatum 194
17.2.9 Influence of C. mucronatum on the cell physiology of human skin cells 194

17.3 Conclusion 196
References 196

18 Gynaecological, Andrological and Urological Problems: An Ethnopharmacological Perspective
Tinde van Andel, Hugo de Boer and Alexandra Towns

18.1 Introduction 199

18.2 Menstrual disorders 200
18.2.1 Dysmenorrhea and uterine spasmolytics 200
18.2.2 Uterine spasmogenics 201

18.3 Postpartum use 201
18.3.1 Puerperal infections 201
18.3.2 Postpartum haemorrhage 202
18.3.3 Perineal healing 202

18.4 Vaginal applications 202
18.5 Female infertility 204

18.6 Andrology 204
18.6.1 Aphrodisiacs and male sterility 204

18.7 Urology 206
References 207

19 Ethnopharmacological Aspects of Bone and Joint Health
Elizabeth M. Williamson

19.1 Introduction 213

19.2 Current views of bone and joint disorders 214
19.3 Traditional views of bone disorders 216
19.3.1 European traditional herbal medicine 216
19.3.2 North America 222
<table>
<thead>
<tr>
<th>Section</th>
<th>Title</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>19.3.3</td>
<td>Traditional Chinese medicine</td>
<td>222</td>
</tr>
<tr>
<td>19.3.4</td>
<td>Ayurveda</td>
<td>223</td>
</tr>
<tr>
<td>19.4</td>
<td>Conclusions</td>
<td>224</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>224</td>
</tr>
<tr>
<td>20</td>
<td>Diabetes and Metabolic Disorders: An Ethnopharmacological Perspective</td>
<td>227</td>
</tr>
<tr>
<td>20.1</td>
<td>Introduction</td>
<td>227</td>
</tr>
<tr>
<td>20.2</td>
<td>Type-2 diabetes</td>
<td>228</td>
</tr>
<tr>
<td>20.2.1</td>
<td>Insulin</td>
<td>228</td>
</tr>
<tr>
<td>20.2.2</td>
<td>Insulin effects in peripheral tissues</td>
<td>229</td>
</tr>
<tr>
<td>20.2.3</td>
<td>Insulin resistance (skeletal muscle and adipose tissue)</td>
<td>229</td>
</tr>
<tr>
<td>20.2.4</td>
<td>Liver</td>
<td>230</td>
</tr>
<tr>
<td>20.2.5</td>
<td>Gut</td>
<td>230</td>
</tr>
<tr>
<td>20.3</td>
<td>Metabolic syndrome</td>
<td>230</td>
</tr>
<tr>
<td>20.4</td>
<td>Case studies</td>
<td>231</td>
</tr>
<tr>
<td>20.4.1</td>
<td>Liver targeting</td>
<td>231</td>
</tr>
<tr>
<td>20.4.2</td>
<td>Gut targeting</td>
<td>232</td>
</tr>
<tr>
<td>20.4.3</td>
<td>Insulin targeting</td>
<td>233</td>
</tr>
<tr>
<td>20.4.4</td>
<td>Obesity and insulin resistance</td>
<td>234</td>
</tr>
<tr>
<td>20.5</td>
<td>Conclusions</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>Acknowledgments</td>
<td>236</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>237</td>
</tr>
<tr>
<td>21</td>
<td>The Ethnopharmacology of the Food–Medicine Interface: The Example of</td>
<td>239</td>
</tr>
<tr>
<td></td>
<td>Marketing Traditional Products in Europe</td>
<td></td>
</tr>
<tr>
<td>21.1</td>
<td>Introduction</td>
<td>239</td>
</tr>
<tr>
<td>21.2</td>
<td>Medicinal products for human use</td>
<td>241</td>
</tr>
<tr>
<td>21.2.1</td>
<td>Legal framework</td>
<td>241</td>
</tr>
<tr>
<td>21.2.2</td>
<td>Definition of medicinal products</td>
<td>241</td>
</tr>
<tr>
<td>21.2.3</td>
<td>Herbal medicinal products</td>
<td>242</td>
</tr>
<tr>
<td>21.3</td>
<td>Food</td>
<td>243</td>
</tr>
<tr>
<td>21.3.1</td>
<td>Definition of food</td>
<td>243</td>
</tr>
<tr>
<td>21.3.2</td>
<td>Food supplements</td>
<td>243</td>
</tr>
<tr>
<td>21.3.3</td>
<td>Fortified food</td>
<td>244</td>
</tr>
<tr>
<td>21.3.4</td>
<td>Novel food</td>
<td>244</td>
</tr>
<tr>
<td>21.3.5</td>
<td>Functional food</td>
<td>245</td>
</tr>
<tr>
<td>21.4</td>
<td>Consumer protection - security and protection against fraud</td>
<td>245</td>
</tr>
<tr>
<td>21.4.1</td>
<td>Food safety</td>
<td>246</td>
</tr>
<tr>
<td>21.4.2</td>
<td>Health claims</td>
<td>246</td>
</tr>
<tr>
<td>21.5</td>
<td>Intended normal use: the distinction between medicinal products and foods</td>
<td>247</td>
</tr>
<tr>
<td>21.6</td>
<td>Conclusion</td>
<td>248</td>
</tr>
<tr>
<td></td>
<td>References</td>
<td>248</td>
</tr>
<tr>
<td>22</td>
<td>Retrospective Treatment-Outcome as a Method of Collecting Clinical Data in Ethnopharmacological Surveys</td>
<td>251</td>
</tr>
<tr>
<td>22.1</td>
<td>Introduction</td>
<td>251</td>
</tr>
<tr>
<td>22.2</td>
<td>Key concepts: clinical data, outcome and patient progress</td>
<td>252</td>
</tr>
<tr>
<td>22.3</td>
<td>Evaluation of the effectiveness and safety of traditional medicines</td>
<td>253</td>
</tr>
</tbody>
</table>
22.4 The role of ethnopharmacologists and ethnobotanists 254
22.5 Collection of clinical data during ethnopharmacological field studies 255
22.6 Example of a method for gathering clinical data during field surveys 255
   22.6.1 Defining the health problem 255
   22.6.2 Research question 255
   22.6.3 Data collection: ask patients! 256
   22.6.4 Getting consent: a much debated topic 256
   22.6.5 Sample size 257
   22.6.6 Statistical analysis and interpretation 257
   22.6.7 Results: a research programme leading to the validation of safe
       and effective phytomedicines 259
22.7 Conclusion: clinical data and field surveys for a positive impact on health 259
References 260

Ethnopharmacology: Regional Perspectives

23 Ethnopharmacology in Sub-Sahara Africa: Current Trends and
Future Perspectives 265
   Mack Mayo, Adeyemi O. Aremu and Johannes van Staden

23.1 Introduction 265
23.2 Role of traditional medicine in Africa 266
23.3 Ethnopharmacological research in sub-Saharan Africa 267
23.4 Challenges of traditional medicine in Africa 269
   23.4.1 Efficacy, toxicology and safety concerns 270
   23.4.2 Shelf-life, post-harvest physiology and storage 271
   23.4.3 Conservation challenges of protecting plant resources 272
23.5 Future perspectives 272
23.6 Conclusions 273
Acknowledgements 273
References 273

24 Ethnopharmacology and Integrative Medicine: An Indian Perspective 279
   Pulok K. Mukherjee, Sushil K. Chaudhary, Shiv Bahadur and Pratip K. Debnath

24.1 Ethnopharmacology and the development of traditional medicine in India 279
24.2 Biological wealth and ancient wisdom 281
24.3 Indian systems of medicine 281
24.4 Ayurveda: the Indian system of medicine 282
   24.4.1 Panchakarma 282
   24.4.2 Validation of classical Ayurvedic formulation 283
   24.4.3 Ayurgenomics 284
   24.4.4 Reverse pharmacology 286
   24.4.5 Ayurinformatics 286
24.5 Siddha 286
24.6 Unani 287
24.7 Traditional knowledge digital library 287
24.8 Integrated approaches for the development of Indian traditional medicine 288
   24.8.1 Strategies and innovations 288
24.9 Conclusion 289
Acknowledgements 290
References 290
## 25 Chinese Medicine: Contentions and Global Complexities

*Anthony Booker*

25.1 Introduction 293

25.2 Ancient concepts meet scientific understanding 294

25.3 Traditional and modern dosage forms and application 296

25.4 Medicinal plant production in China 296

25.5 Quality and safety 297

25.6 Aristolochic acids 298

25.7 Regulatory requirements 298

25.8 Training practitioners of TCM 299

25.9 Future prospects 300

References 301

## 26 Chinese Medicinal Processing: A Characteristic Aspect of the Ethnopharmacology of Traditional Chinese Medicine

*Ping Guo, Eric Brand and Zhongzhen Zhao*

26.1 Introduction 303

26.2 Definition, methods and historical changes in Chinese medicinal processing 304

26.2.1 Definition 304

26.2.2 Methods 304

26.2.3 Historical changes 308

26.3 Present state of Chinese medicinal processing 310

26.3.1 Inconsistency of ancient and current processing methods 310

26.3.2 Inconsistency of processing practice in different provinces of China 310

26.3.3 Differences in decoction pieces between Hong Kong and mainland China 311

26.3.4 Differences in national pharmacopoeias regarding medicinal processing 311

26.3.5 Lack of objective quality control standards 312

26.3.6 Progress in research 313

26.4 Prospect for future developments in Chinese medicinal processing 315

References 315

## 27 A South-East Asian Perspective on Ethnopharmacology

*Pravit Akarasereenont, Marianne J.R. Datiles, Natchagorn Lumlerdkij, Harisun Yaakob, Jose M. Prieto and Michael Heinrich*

27.1 Introduction 317

27.2 Ethnopharmacology in Thailand 319

27.3 Ethnopharmacology in Malaysia 322

27.3.1 Malay traditional medicine 322

27.3.2 Clinical integration of the Malay traditional medicines 323

27.3.3 Modern phytotherapeutic products and food supplements from Malay traditional medicinal plants 324

27.3.4 The future direction of Malay TM 325

27.4 Ethnopharmacology in Indonesia 325

27.5 Ethnopharmacology in the Philippines 326

27.6 Ethnopharmacology in Vietnam 328

27.7 Ethnopharmacology in Myanmar, Lao PDR and Cambodia 328

27.8 Ethnopharmacology in Singapore and Brunei 328

27.9 Conclusion 328

Acknowledgement 329

References 329
28  **Historical Approaches in Ethnopharmacology**  
*Andreas Lardos*

28.1 Introduction  
28.2 Historical texts in ethnopharmacological research  
28.2.1 Documentation of (mainly) medicinal plant knowledge  
28.2.2 Evaluation of medicinal plant knowledge and identification of potential plant candidates  
28.2.3 Development of (medicinal) plant knowledge  
28.3 Methodological aspects  
28.4 Challenges in the analysis of historical texts  
28.5 Opportunities offered by a historical approach  
28.6 Conclusions

References

29  **Medical Ethnobotany and Ethnopharmacology of Europe**  
*Manuel Pardo-de-Santayana, Cassandra L. Quave, Renata Sõukand and Andrea Pieroni*

29.1 Introduction  
29.2 A brief history of European medicinal plants studies  
29.3 Modern European medico-ethnobotanical studies  
29.3.1 The development of ethnobotanical studies in Europe  
29.3.2 Recent medico-ethnobotanical studies in Europe  
29.4 European ethnomedicinal flora  
29.5 Adaptation, syncretism and resilience of traditional pharmacopoeias  
29.6 Pharmacological studies of European medicinal plants  
29.7 Concluding remarks

References

30  **Ethnopharmacology in the Eastern Mediterranean and the Middle East: ’The Sun Rises from the East, but Shines on the Eastern Mediterranean’**  
*Erdem Yesilada*

30.1 Introduction  
30.2 Ethnobotany and ethnopharmacology in the Balkan region  
30.3 Modern ethnobotany and ethnopharmacology in the Middle East  
30.4 Ethnobotany and ethnopharmacology in Turkey  
30.5 Concluding remarks

References

31  **Ethnopharmacology in Australia and Oceania**  
*Graham Lloyd Jones and Nicholas J. Sadgrove*

31.1 Introduction  
31.1.1 Australian ethnobotany  
31.1.2 Ethnobotany in Oceania  
31.2 Ethnopharmacological ’classics’  
31.2.1 Scopolamine from the Australian *Duboisia*  
31.2.2 Polynesian breadfruit and kava used throughout Oceania  
31.3 Australian aromatic plants  
31.3.1 Eucalyptus  
31.3.2 *Melaleuca alternifolia* (tea tree oil)